Related Experiment Video
Updated: Aug 2, 2026

12:35
Simultaneous Mapping and Quantitation of Ribonucleotides in Human Mitochondrial DNA
Published on: November 14, 2017
Short, single-stranded oligonucleotides mediate targeted nucleotide conversion using extracts from isolated liver
Betsy T Kren1, Phillip Y Wong, Clifford J Steer
1Department of Medicine, University of Minnesota Medical School, Minneapolis, MN 55455, USA. krenx001@tc.umn.edu
DNA Repair
|April 26, 2003
Summary
Mitochondria possess enzymes for correcting single-point mutations using single-stranded oligonucleotides (ONs). This DNA repair mechanism differs from that used by chimeric ONs and may offer new treatments for mitochondrial diseases.
Area of Science:
- Mitochondrial Biology
- Molecular Genetics
- DNA Repair Mechanisms
Background:
- Human diseases often stem from single-point mutations in mitochondrial DNA.
- Previous work showed rat liver mitochondria can modify DNA using chimeric oligonucleotides (ONs).
- Nuclear and mitochondrial DNA repair pathways involve different factors and mechanisms.
Purpose of the Study:
- To investigate if mitochondria have the enzymatic machinery for single-stranded (SS) oligonucleotide-mediated DNA alterations.
- To determine if SS ONs can correct point mutations in mitochondrial DNA.
Main Methods:
- In vitro DNA repair assays using mutagenized plasmids.
- A bacterial read-out system to detect nucleotide modifications.
- Protein extracts from purified rat liver mitochondria and nuclei were utilized.
Main Results:
- Mitochondrial and nuclear extracts showed similar levels of site-specific nucleotide modifications with SS ONs.
- Quiescent liver extracts yielded higher conversion rates than regenerating liver extracts.
- SS ON-mediated correction appears to be a single-strand, strand-transfer process.
Conclusions:
- Mitochondria possess factors necessary for correcting single-point mutations using SS ONs.
- These factors differ from those required for chimeric ON-mediated DNA repair.
- Unmodified SS ONs may offer a novel therapeutic strategy for mitochondrial diseases.

